Obstetrics and Gynecology

Gynecologic Oncology

Phoenix Integrated Residency in Obstetrics and Gynecology Research Wall of Fame, 2015
Second place in the Ray Jennett Society Resident Research Night, 2016St. Joseph’s Resident Clinical Research Award, 2016

My research has focused clinical research describing new therapeutic options, and management strategies providing targeted, patient-centered care in gynecologic oncology.  

1. Minion LE, Tierney B, Morris P, Crotzer D. The utility of collecting cytologic washings during robotic total laparoscopic hysterectomy for endometrial cancer. 2012 Western Association of Gynecologic Oncologists Annual Meeting, Huntington Beach, CA, June 2012.
2. Minion LE, Tewari KS, Chan JK, Penson RT, Cohn DE, Monk BJ. A trial-based economic assessment of bevacizumab and chemotherapy verses chemotherapy alone for advanced cervical cancer:  a cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240. The 18^th European Society of Gynaecological Oncology International Meeting, Liverpool, UK, October 2013.
3. Minion LE, Shields KS, Farley J. Outcomes of conservative surgical management of stage IA and IBI cervical cancer. 44^th Annual Felix Rutledge Society Annual Meeting, Scottsdale, AZ, May 17, 2014.
4. Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. 2014 Western Association of Gynecologic Oncologists Annual Meeting, Truckee, CA, June 2014.
5. Minion LE, Chase DM, Farley JH, Willmott LJ, Monk BJ.  Safety and Efficacy of Salvage Nano-Particle Albumin Bound Paclitaxel in Recurrent Cervical Cancer:  A Feasibility Study.  Abstract accepted for an oral presentation at Western Association of Gynecology Oncologists Annual Meeting, Santa Rosa, CA, June 2015.
6. Minion LE, Slaughter GT, Gardner AB, Chan JK, Monk BJ.  Demographics, tumor characteristics and survival differ between females and males with leiomyosarcoma.  Society of Gynecologic Oncology Annual Meeting, San Diego, CA, March 2016.
7. Wolford JE, Bai J, Eskander RH, Keller R, Minion LE, Chan JK, Monk BJ, Tewari KS. A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth-line treatment of recurrent ovarian cancer.  American Society of Clinical Oncology, Chicago, IL, June 2016.
8. Wolford JE, Bai J, Eskander RH, Keller R, Minion LE, Chan JK, Monk BJ, Tewari KS.  Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.  American Society of Clinical Oncology, Chicago, IL, June 2017.
9. Minion LE, Liu-Smith F, Sarrin V, Meyskens FL, Randall LM.  Preclinical investigation of DNA histone deacetylase inhibition in ovarian cancer.  2017 Western Association of Gynecologic Oncologists Annual Meeting, Rancho Mirage, CA, June 2017.
10. Wolford JE, Bai J, Minion LE, Keller R, Eskander RH, Chan JK, Monk BJ, Tewari KS.  Cost-effectiveness of maintenance therapy in advanced ovarian cancer:  Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.  American Society of Clinical Oncology, Chicago, IL, June 2018.
11. Minion LE, Tofig B, Randall LM, Kaiser P. p53 Restoration in Ovarian Carcinoma Harnessing a Genetic Aberration. 2019 Western Association of Gynecologic Oncologists Annual Meeting, Huntington Beach, CA, June 2019